Viatris Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Viatris Inc. or Bio-Techne Corporation?

In the competitive landscape of the pharmaceutical and biotechnology sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Viatris Inc. and Bio-Techne Corporation have shown distinct approaches to handling these costs.

From 2014 to 2023, Bio-Techne Corporation's SG&A expenses grew steadily, starting at approximately $60 million and reaching nearly $400 million. This represents a growth of over 550%, reflecting their strategic investments in expansion and innovation. In contrast, Viatris Inc. exhibited a more volatile pattern, with expenses peaking at around $4.65 billion in 2023, a significant increase from $1.5 billion in 2014.

While Bio-Techne's consistent growth suggests a controlled and strategic approach, Viatris's fluctuations may indicate aggressive scaling or restructuring efforts. The absence of 2024 data for Viatris suggests potential changes in their financial strategy. Understanding these trends can offer valuable insights into each company's operational efficiency and strategic priorities.